Delivra Health Brands (DHB) Q4 2025 earnings summary

Executive summary

• Achieved year-over-year revenue growth, with figures reported as 80% and 8% for fiscal 2025, driven by strong performance in Dream Water and LivRelief brands across e-commerce and retail channels.

• Maintained profitability with positive adjusted EBITDA for the third consecutive year, though adjusted EBITDA declined to $643,000 due to increased marketing and innovation investments.

• Built a strong balance sheet, increasing inventory by over 86% to support future growth without external funding.

• Expanded distribution and innovation across major retail, e-commerce, and travel channels in North America and internationally.

• Revenue decline in LivRelief Infused business partially offset overall gains; new route-to-market strategy being implemented.

Financial highlights

• Net revenue reached $13,370,000 in fiscal 2025, up from $12,378,000 in fiscal 2024, an 8% increase year-over-year.

• Compound annual growth rate of 13% over the past four years.

• Maintained a 51% gross margin despite rising input costs and channel mix changes.

• Adjusted EBITDA was $643,000, down from $871,000, reflecting increased investments in marketing and innovation.

• Net loss from continuing operations was $1,190,000 compared to net profit of $876,000 in the prior year.

Outlook and guidance

• Management anticipates improved top and bottom-line results in the coming year, supported by strong retail traction, global expansion opportunities, and a pipeline of new products.

• Expecting improved adjusted EBITDA in fiscal 2026.

• Plans to expand into new international markets, including Latin America and Europe.